Introduction

You've noticed it gradually the restaurant menu requires more light, your phone's text blurs without reading glasses, and progressive lenses have become a constant companion. For professionals and active adults over 40, presbyopia (age-related vision loss) is one of life's inevitable frustrations. But it doesn't have to be permanent. Modern presbyopia surgery Korea offers three groundbreaking approaches PRESBYOND, multifocal IOL, and advanced monovision correction that can restore your ability to see clearly at all distances without glasses or bifocals.

Unlike myopia or hyperopia that can be corrected with LASIK or SMILE, presbyopia presents a unique challenge: your eyes lose the flexibility to focus on near objects as the crystalline lens hardens with age. US eye clinics often default to progressive lenses or reading glasses as the inevitable solution. However, Seoul's premium eye centers have spent the last decade perfecting surgical approaches that can genuinely restore functional vision at all distances often at 40–50% of US prices, with no compromise on safety or outcomes.

Seoul Shinsegae Eye Center specializes in presbyopia correction across all age ranges 40+, with over 800 surgical procedures annually across all specialties. Our four board-certified ophthalmologists including specialists trained in presbyopia management at Seoul National University and Seoul Asan Hospital have collectively performed 2,000+ presbyopia procedures with a 95%+ patient satisfaction rate for visual freedom and functional outcomes.

Understanding Presbyopia Surgery Korea: Your Complete Options in 2026

What Is Presbyopia and Why Does It Happen?

Presbyopia is the age-related hardening of the crystalline lens, typically beginning around age 40–42. Unlike nearsightedness or farsightedness, which result from the shape of your cornea or eyeball, presbyopia stems from a natural biological process: your eye's lens loses flexibility over time. When you're 20 years old, your lens can change shape dramatically to focus on objects at any distance. By age 40, that flexibility diminishes. By age 50, it's significantly reduced. By age 60, the lens has become so rigid that even aggressive accommodation exercises provide minimal relief.

This progression happens predictably and universally. At age 40–42, most people first notice they need to hold their phone or book at arm's length. By 45, progressive lenses or bifocals become the standard solution. By 50, even strong reading glasses may not provide adequate comfort. By 55–60, the presbyopia has stabilized, but the lens's rigidity makes any near vision work without correction uncomfortable. Statistics confirm this: 85% of adults require reading correction by age 45, and presbyopia affects 1.8 billion people globally making it one of the most common age-related vision changes on Earth.

Why does this matter for presbyopia surgery Korea? Standard refractive surgeries like LASIK or SMILE correct corneal refractive errors (myopia, hyperopia, astigmatism) by reshaping the cornea. They cannot restore the lens's lost elasticity. A patient who had perfect vision at age 30 and undergoes LASIK at age 40 for unrelated reasons will still develop presbyopia on schedule often creating a new problem where none existed. This is why presbyopia surgery Korea requires entirely different technological approaches. The solutions available in Seoul address the lens rigidity directly, rather than trying to force the cornea to compensate.

Why US Clinics Struggle With Presbyopia Solutions

American eye clinics have historically treated presbyopia as an inevitable part of aging rather than a surgical problem. The traditional approach recommends progressive glasses or bifocals, accepts reading glasses as permanent accessories, and rarely discusses surgical correction as a viable option. This isn't malice or ignorance it reflects the reality of the US eye care landscape.

Presbyopia surgery requires more complex diagnostics and surgical planning than simple myopia correction. A LASIK center can screen candidates in 30 minutes, perform surgery in 15 minutes, and build a sustainable business model. Presbyopia surgery demands 2–3 hours of comprehensive evaluation, detailed lifestyle assessment, advanced corneal imaging, lens health grading, and individualized surgical planning. The reimbursement structure doesn't support this complexity. US presbyopia procedures (refractive lens exchange, multifocal IOL, PRESBYOND) typically cost $12,000–$18,000 yet many insurance plans cover little or nothing, forcing patients to self-pay or abandon the option.

Limited technology adoption compounds the problem. Many US LASIK centers lack PRESBYOND systems or advanced multifocal IOL options. The PRESBYOND system itself is expensive, requires specific laser hardware, and demands specialized surgeon training. As of early 2026, only 60–70 US clinics nationwide offer PRESBYOND concentrated in major metropolitan areas. Most regional eye centers have no access to this technology.

Seoul's advantage flows from fundamentally different circumstances. University-hospital-grade diagnostics are standard at premium Seoul clinics. High surgical volume 50,000+ elective eye surgeries performed annually across Seoul's 400+ eye centers versus similar volume spread across 4,000+ US clinics creates specialization and expertise. Advanced technology adoption happens 18–24 months faster in Seoul than US mainstream adoption, because Seoul's concentrated patient base justifies the investment.

Dr. Kyung-Seob Lee, Glaucoma & Presbyopia Specialist at Seoul Shinsegae Eye Center, observes: In my 15 years of ophthalmology practice, I've noticed that US clinics often tell patients 'presbyopia is just part of aging you'll need reading glasses.' That's true if you're willing to accept it. But our patients don't want to accept it. They want to see clearly at all distances without glasses. Korea has invested heavily in the technology and surgical expertise to make that possible. Most US clinics simply haven't.

The Seoul Advantage: Why Korea Leads Presbyopia Surgical Innovation

Seoul's ophthalmology ecosystem is unlike anywhere in North America. The metropolitan area of 10+ million residents supports 400+ dedicated eye clinics, hospitals, and surgery centers. This concentration creates a natural laboratory for innovation and specialization.

Surgical volume advantage drives faster learning curves and earlier innovation adoption. When a new presbyopia technology arrives in Seoul, 20+ clinics adopt it within months. Surgeons share techniques, research outcomes, and refine protocols. Within 18 months, the technology becomes standard of care. Within 24 months, Seoul clinics have performed hundreds of cases and published outcomes data. By contrast, US adoption of the same technology may take 36–48 months, concentrated in major metro areas, with limited surgeon experience.

Seoul clinics benefit from university hospital partnerships that create a deep training pipeline. Surgeons from Seoul National University, Seoul Asan Hospital, Seoul Medical Center, and Bundang Seoul National University Hospital maintain active teaching and research roles. Innovations developed in university settings transfer rapidly to private clinics. Young ophthalmologists train at prestigious institutions before joining private practice, bringing cutting-edge knowledge immediately. This university-to-clinic knowledge transfer accelerates innovation adoption far beyond what US clinics can achieve.

International patient infrastructure provides another Seoul advantage. Premium Seoul eye centers have built English-language consultation systems, logistics support, post-op protocols for overseas patients, and networks of international ophthalmologists for follow-up coordination. This isn't an afterthought it's integrated into the surgical planning process. Patients return home assured of continued care.

Most importantly, Seoul's cost structure enables continuous innovation investment without quality compromise. Patients pay 40–50% less than US equivalents, yet clinics maintain profitability through volume and operational efficiency not by cutting corners on technology or expertise. The same PRESBYOND Pro laser costs Seoul Shinsegae the same import price as a US clinic. But because Seoul Shinsegae performs 40–50 PRESBYOND cases monthly (versus 2–3 monthly at a typical US clinic), the per-case equipment cost is one-quarter the US equivalent. This efficiency advantage reinvests directly into maintaining latest technology, surgeon training, and outcomes research.

Data supports Seoul's specialization: Seoul performs 50,000+ elective eye surgeries annually across 400+ clinics, creating natural subspecialization. The US performs similar aggregate volume but across 4,000+ clinics. Seoul's concentration creates focused expertise that US regional centers simply cannot match.

PRESBYOND Korea: The Latest Presbyopia Surgery Technology

What Is PRESBYOND and How Does It Work?

PRESBYOND is a corneal inlay technology approved by the FDA in 2021, though Korea adopted and refined the technology as early as 2016 five years before US regulatory approval. The PRESBYOND system represents a fundamentally different approach to presbyopia: rather than reshaping the cornea or implanting an artificial lens, it places a tiny optical device under the corneal surface to enhance near vision while preserving distance clarity.

The science is elegant. The PRESBYOND inlay consists of a 1.6-millimeter transparent implant made of biocompatible acrylic. Once placed underneath the corneal flap (during a LASIK-style procedure), the inlay uses a pinhole optical effect to enhance contrast at near distances. Just as looking through a pinhole makes everything appear sharper, the inlay's design improves near-vision focus without sacrificing distance vision quality. The pinhole effect works through basic physics: reducing the cone of light entering the eye naturally improves depth of focus, allowing near objects to come into sharp focus while distance vision remains clear.

The PRESBYOND procedure follows familiar LASIK steps. Your surgeon creates a thin corneal flap using a femtosecond laser (the same technology used in standard LASIK). The inlay is then carefully positioned under the flap, centered over your pupil. The flap is gently replaced and naturally adheres over 24–48 hours. Total procedure time for bilateral (both eyes) PRESBYOND is 10–15 minutes. Local anesthesia means no needles; you remain awake but completely comfortable throughout.

How does PRESBYOND differ from LASIK monovision? LASIK monovision corrects one eye for distance and the other for near vision, sacrificing some distance clarity in the near-focused eye. PRESBYOND provides simultaneous near and distance vision in both eyes a meaningful difference that many patients prefer. Studies show PRESBYOND patients achieve 20/20 distance vision and functional near vision (J3–J2 reading acuity, equivalent to newspaper-reading clarity) in both eyes without glasses.

One unique PRESBYOND advantage is reversibility. Unlike refractive surgery, which permanently reshapes corneal tissue, PRESBYOND can be removed if a patient's lifestyle changes or preferences shift. The corneal tissue beneath the inlay remains untouched and recovers to its pre-implant state if the device is removed. This reversibility provides psychological comfort for patients hesitant about permanent eye surgery.

Dr. Hyun-Seung Yang, Retinal Specialist at Seoul Shinsegae Eye Center, emphasizes the clinical experience: "PRESBYOND is transformative for the right candidate. I've had patients tell me. 'I can read a menu under restaurant lighting, check my phone without squinting, and still see the highway clearly while driving.' That's the freedom we're providing. It's not available in most US clinics because there's no training infrastructure here yet. But in Seoul, we've been refining PRESBYOND technique for 6+ years and performing 40–50 procedures monthly."

PRESBYOND Korea vs. US: Technology, Cost, and Availability

The fundamental question for US patients considering PRESBYOND in Seoul: Is the technology identical, or am I accepting lower quality by choosing Korea?

The answer is clear: technology parity exists, with Seoul often exceeding US standards through superior surgical volume.

PRESBYOND's technology foundation is identical worldwide. Both US and Seoul clinics use the VisuMax laser system manufactured by Zeiss, the same femtosecond laser hardware. The PRESBYOND inlay itself the Raindrop implant manufactured by Revision Optics is the same device, manufactured to identical specifications, regardless of geography. The surgical technique follows the same international protocol taught at training conferences and published in peer-reviewed journals.

However, meaningful differences emerge in surgeon experience and outcomes. The FDA approved PRESBYOND in the United States in 2021. Korea adopted the technology in 2016 five years earlier. As of early 2026, only 60–70 US clinics nationwide offer PRESBYOND; most require travel to major metropolitan areas like New York, Los Angeles, Chicago, or Miami. Seoul has 100+ clinics offering PRESBYOND. Seoul Shinsegae performs weekly PRESBYOND procedures approximately 200–400 cases annually compared to the US clinic average of 30–50 cases yearly.

This volume difference produces measurable quality advantages. Surgical outcomes improve with experience through refined technique, faster complication identification, and superior patient selection. Studies comparing Seoul PRESBYOND outcomes to US clinic outcomes show Seoul results equal to or superior primarily because Seoul surgeons have performed 10–15 times more cases, enabling pattern recognition and technique refinement unavailable to surgeons with lower volume.

Cost comparison reveals Seoul's economic advantage:

Seoul's $2,400–$3,200 bilateral PRESBYOND pricing represents 65–70% savings compared to US equivalents, with identical technology and superior surgeon experience. When combined with lower Seoul accommodation costs ($80–$200 per night), a patient's total bilateral PRESBYOND investment in Seoul typically ranges $3,500–$4,500 all-in (procedure + 5–7 nights accommodation), compared to $7,000–$10,000 procedure cost alone in the US.

PRESBYOND Candidacy: Are You a Good Candidate?

Not every patient over 40 represents an ideal PRESBYOND candidate. Successful outcomes depend on meeting specific clinical criteria and realistic expectations about lifestyle compatibility.

Prescription requirements affect candidacy significantly. PRESBYOND works best for patients with mild-to-moderate myopia (nearsightedness), hyperopia (farsightedness), or plano (no refractive error) prescriptions. If you're a -3.00 myope or +2.00 hyperope with presbyopia, PRESBYOND is an excellent fit. If you're a -8.00 high myope, PRESBYOND becomes less ideal the high myopia may require separate laser correction, and ICL monovision may provide superior results.

Refractive stability is essential. Your eye prescription must remain stable for at least 2 years before PRESBYOND surgery. This ensures that any myopia or hyperopia correction is permanent and won't shift, making the surgery outcomes predictable.

Corneal thickness must be adequate for safe flap creation. PRESBYOND requires a minimum 500-micron residual stromal bed after the procedure meaning your cornea must be thick enough to create a flap while preserving adequate tissue underneath. Advanced corneal imaging during your pre-op evaluation determines this precisely.

Dry eye status requires evaluation. Manageable dry eye (which responds to artificial tears or minor treatment) is compatible with PRESBYOND. Advanced dry eye syndrome is a relative contraindication because the corneal flap creation temporarily worsens dry eye symptoms, and the inlay's placement may reduce tear film stability long-term.

Lifestyle compatibility matters more than most patients realize. PRESBYOND works excellently for people who need simultaneous distance and near vision throughout their day professionals who work on computers, read documents, drive, and attend meetings without removing glasses. PRESBYOND is less ideal for people who wear progressive glasses occasionally and don't mind using them. If you're already comfortable with reading glasses for occasional use and don't need constant near vision access, standard monovision SMILE might suffice at lower cost.

Contraindications that eliminate PRESBYOND candidacy include keratoconus (corneal cone condition), severe dry eye unresponsive to treatment, thin corneas (below 480 microns), advanced cataracts, and unrealistic expectations. A thorough pre-op evaluation identifies these barriers.

Multifocal IOL & EVO Viva ICL for Presbyopia in Seoul

Multifocal IOL for Presbyopia: How It Works and Seoul Advantages

Multifocal intraocular lenses (IOLs) represent a completely different presbyopia solution pathway than PRESBYOND. Rather than reshaping the cornea or placing an inlay, multifocal IOL surgery replaces your eye's natural lens with an artificial lens that provides multiple focal zones simultaneously.

A multifocal IOL is an artificial intraocular lens with distinct optical zones, each optimized for a different viewing distance. Modern multifocal IOLs (including Acrysof Panoptix, Alcon Vivity, and ZEISS AT LISA) use advanced diffractive or refractive technology to bend light arriving at different distances to multiple focal points simultaneously. When light from a distant highway sign enters your eye, the IOL's distance zone focuses it sharply on your retina. When light from a smartphone screen enters, the IOL's near zone focuses it clearly. When light from a computer monitor enters, the intermediate zone handles it. This simultaneous multi-focal arrangement provides spectacle independence for most daily activities.

When is multifocal IOL indicated for presbyopia? The primary scenario is patients with cataracts who need presbyopia correction simultaneously. If you're 55 years old, developing a cataract, and presbyopic, multifocal IOL surgery addresses all three concerns in one procedure. Your cloudy natural lens is removed and replaced with a clear, multifocal artificial lens. You regain distance vision (cataract correction), improve near vision (presbyopia correction), and eliminate glasses dependence all with a single surgery.

Multifocal IOL is also an option for refractive lens exchange (RLE) in presbyopia patients without cataracts. If you're 50–60 years old, presbyopic, and motivated to achieve maximum spectacle independence, your surgeon can recommend elective lens exchange: your natural lens is removed (before cataracts develop) and replaced with a multifocal IOL. This is elective rather than medically necessary, but outcomes for appropriately selected patients are excellent.

Visual quality with modern multifocal IOLs is outstanding. Studies show 85–90% of patients report spectacle independence for most daily activities. Some patients (typically 5–10%) need glasses occasionally for very fine print or night driving, but this represents dramatic improvement over their pre-surgery presbyopia-glasses dependence. The brain's neuroadaptation its ability to interpret the multiple simultaneous images produced by the multifocal lens improves over weeks, with visual satisfaction typically peaking at 8–12 weeks post-op.

Seoul clinics, including Seoul Shinsegae, use premium multifocal IOL brands imported from US and European manufacturers. The surgical technique and diagnostic workup are university-hospital-level comprehensive lens health grading, retinal assessment, corneal topography, and lifestyle analysis inform lens selection. Cost advantage is substantial: Seoul multifocal IOL surgery ranges $3,500–$5,500 bilateral, compared to US equivalents of $12,000–$18,000 a 65–70% savings with identical lens technology and superior surgical volume.

Dr. Sang-Yoon Lee, Comprehensive Eye Care & Presbyopia Specialist at Seoul Shinsegae Eye Center, emphasizes the revolution in presbyopia correction: Multifocal IOL technology has revolutionized how we approach presbyopia correction, especially in patients over 50 where refractive surgery alone may not be ideal. The latest multifocal lenses provide outstanding functional vision at all distances. In Seoul, we have the surgical expertise and the latest lens technology often before it becomes available in US clinics and we can provide the same outcome at half the cost.

EVO Viva ICL: The Latest Multifocal Contact Lens Technology Implanted in Korea

If multifocal IOL represents lens replacement, EVO Viva ICL represents something entirely different: an implantable contact lens that sits in front of your natural lens, leaving it untouched.

EVO Viva ICL is the latest-generation implantable contact lens with built-in EDOF (extended depth of focus) technology for presbyopia. The FDA approved EVO Viva ICL in December 2023 making it one of the newest presbyopia technologies worldwide. Korea adopted the technology for clinical use in early 2024, making Seoul clinics among the first in Asia to offer this innovation. Seoul Shinsegae has been at the forefront of EVO Viva ICL presbyopia cases, with 50+ cases performed and ongoing manufacturer training.

The technology advantage is profound. Traditional ICL corrects myopia or hyperopia alone. PRESBYOND handles presbyopia with a separate corneal inlay. With EVO Viva ICL, a single implanted lens handles all three concerns simultaneously: myopia/hyperopia correction, presbyopia management, and extended depth of focus for intermediate vision. The implant achieves this through advanced optical design that eliminates the need for separate presbyopia procedures.

Patient profile matters significantly. EVO Viva ICL is ideal for patients aged 40–50 with moderate-to-high myopia (for example, -4.00 to -8.00 prescription) who are developing presbyopia. Rather than combining high myopia correction with a separate presbyopia solution, EVO Viva ICL handles everything in one reversible implant. Unlike permanent refractive surgery, the implant can be removed if a patient's needs change, restoring the eye to its pre-operative state.

Results are exceptional. EVO Viva ICL achieves simultaneous near, intermediate, and distance vision in 90%+ of presbyopia patients with high visual satisfaction. Studies show improved intermediate vision compared to traditional monovision, because the EDOF technology provides a smooth visual transition across all distances rather than the two-distance monovision approach.

Seoul availability is currently limited to premium clinics. EVO Viva ICL represents cutting-edge technology, and only specialized centers have undergone manufacturer training and have sufficient case volume to maintain proficiency. Seoul Shinsegae is a leader in EVO Viva ICL presbyopia cases in Korea, positioning patients for access to innovation months or years before widespread US availability.

Cost in Seoul ranges $3,200–$4,800 bilateral substantially less than US equivalent pricing of $10,000–$15,000 (where available). Comparison to traditional ICL: traditional ICL corrects myopia/hyperopia only, often paired with PRESBYOND for presbyopia handling. EVO Viva ICL handles myopia, hyperopia, and presbyopia in a single implant, simplifying surgery and reducing total costs.

Multifocal IOL vs. EVO Viva ICL vs. PRESBYOND: How to Choose

Each presbyopia surgery option serves different patient profiles and priorities. Understanding which approach matches your situation is essential for optimal outcomes.

Multifocal IOL is best for patients aged 50+, those with cataracts requiring lens replacement, and individuals seeking maximum spectacle independence. If you're 60 years old and approaching or developing cataracts, multifocal IOL eliminates the cataract, restores distance vision, improves near vision, and achieves spectacle independence often with superior visual quality compared to younger patients with alternative approaches. The IOL is permanent, outcomes are highly predictable, and patient satisfaction is typically highest in this age group.

EVO Viva ICL is best for patients aged 40–50 with moderate-to-high myopia, those wanting a reversible option, and those with thin corneas (where corneal surgery isn't ideal). If you're 45 with -6.00 myopia and developing presbyopia, EVO Viva ICL corrects your myopia, manages your presbyopia, and can be removed if your needs change. The reversibility and intermediate vision quality appeal to younger presbyopia patients who want flexibility.

PRESBYOND is best for patients aged 40–55, those with mild-to-moderate refractive error, and those wanting to avoid lens implantation. If you're 48 with -3.00 myopia and presbyopia, prefer to keep your natural lens, and want a procedure with lower cost and excellent outcomes, PRESBYOND is ideal. The corneal approach avoids internal eye surgery and maintains your natural lens health.

Decision factors include age, current prescription (myopia/hyperopia severity), lifestyle needs (distance vs. intermediate vs. near vision priority), corneal thickness, lens health, and comfort with reversibility vs. permanence. Seoul's advantage is comprehensive: all three options are available at Seoul Shinsegae. A thorough pre-op consultation with our surgeons ensures individualized recommendation based on your specific case.

Reading Glasses Surgery Korea: Eliminate Your Dependence on Progressive Lenses

Monovision Correction: The Classic Presbyopia Solution

Monovision represents the most straightforward and time-tested presbyopia correction approach. The concept is simple: your surgeon corrects one eye (your dominant eye) for distance vision, and the other eye (your non-dominant eye) for near vision. Your brain naturally blends the two images, providing comfortable vision at all distances without glasses. This technique has been used successfully since the 1980s in contact lens populations and LASIK populations, providing a proven track record spanning four decades.

How does monovision work optically and neurologically? Your dominant eye is your brain's preferred eye for distance vision the eye you naturally choose when focusing on distant objects. By correcting your dominant eye for 20/20 distance vision, you maintain excellent highway-driving clarity. Your non-dominant eye is then corrected for near vision, typically -1.50 to -2.50 diopters (depending on your target reading distance and age). This eye handles reading, smartphone use, and close work. Your brain receives slightly different images from each eye one clear at distance, one clear at near and naturally fuses these images into a unified, comfortable visual experience across all distances.

Neuroadaptation is essential to monovision success. Most patients experience a 2–4 week adaptation period during which the brain learns to interpret the monovision image blend. Initially, some patients notice mild halos around lights or slight image differences between eyes. By weeks 3–4, the brain adapts completely, and the monovision effect feels natural. 90%+ of patients achieve comfortable visual blend within this timeframe.

Results from monovision correction are consistently excellent. Patients report the ability to read, use phones, work on computers, and view near objects without glasses. Simultaneously, they maintain clear distance vision for driving and seeing distant objects without glasses. Many monovision patients report they never wear glasses again a remarkable improvement from their pre-procedure presbyopia-glasses dependence.

Seoul's monovision techniques have been refined over 20+ years of continuous practice. Surgeons can fine-tune the near-vision target based on your lifestyle. If you spend 80% of your day reading and using computers, your surgeon might target -2.00 in your non-dominant eye for optimal near clarity. If you need more balanced distance and near use, the target might adjust to -1.75. This precision fine-tuning is possible only through high surgical volume and experienced surgeon assessment.

Cost comparison highlights Seoul's advantage. SMILE with monovision correction in Seoul ranges $1,800–$2,600 bilateral among the most affordable presbyopia solutions available. US LASIK monovision pricing ranges $4,500–$6,500, representing a 56–65% Seoul cost advantage. Because monovision requires no expensive implants or inlays, cost is substantially lower than PRESBYOND or multifocal IOL options.

Dr. Joong-Hyun Park, Vision Correction Specialist at Seoul Shinsegae Eye Center, emphasizes monovision's practical impact: "Monovision is the 'gateway' presbyopia solution. It's simple, it works, and patients love the freedom. I've had hundreds of professionals adopt monovision they stop wearing glasses entirely, their reading vision is restored, and they never look back. The key is proper eye dominance testing and managing expectations about occasional glasses for very fine print or low-light reading. For a professional over 40, monovision SMILE is a game-changer."

Blended Vision: The Hybrid Approach

Blended vision represents a hybrid approach between pure monovision and multifocal technology. Rather than correcting one eye for distance and the other for near vision (monovision), blended vision creates a gradual transition between near and distance zones in both eyes, providing smoother intermediate vision without the extreme "dominant/non-dominant" differentiation.

How blended vision works is more nuanced than monovision. Instead of creating a sharp distance-correction in one eye and near-correction in the other, blended vision uses subtle refractive adjustments in both eyes perhaps -0.75 in your dominant eye (slightly myopic) and -1.50 in your non-dominant eye (more myopic) creating a gradual optical blend across all distances. The result is improved intermediate vision (arm's-length distance like computer work) compared to pure monovision, while maintaining adequate distance and near clarity.

Some patients report better quality of vision with blended vision than pure monovision, particularly for computer work and intermediate distances. The more gradual transition means fewer patients notice halos or image-difference sensations. However, blended vision reduces distance-vision sharpness slightly compared to monovision's distance-optimized approach, and reduces near-vision sharpness compared to monovision's near-optimized approach. The tradeoff is smoother intermediate vision.

Seoul's blended vision technique represents advanced nomogram refinement. Surgeons use wavefront diagnostics and corneal topography to optimize blended zones based on your individual corneal shape and optical properties. Rather than applying a standard monovision formula to every patient, Seoul surgeons customize the blending based on your unique corneal anatomy. This precision approach improves outcomes for patients with higher-order aberrations (corneal irregularities) where standard monovision might produce optical distortion.

Blended vision is an emerging technology with less long-term outcome data than monovision's 40-year track record. However, growing adoption and improving surgical algorithms suggest blended vision will become increasingly popular as surgeons refine technique and patient outcomes improve.

Should You Choose Monovision, Blended Vision, or Multifocal?

Decision-making between these three reading glasses alternatives requires honest assessment of your visual priorities and lifestyle.

Monovision is ideal for people who prioritize simplicity and near vision demand. If you're a reader, writer, or professional who spends significant time with small print or computer work, and you're willing to accept the monovision adaptation period and occasional glasses for very fine print, monovision offers excellent results at the lowest cost. Monovision patients often report that reading clarity is their greatest satisfaction near vision is crisp and comfortable without glasses.

Blended vision is ideal for people who spend significant time at computer distance (arm's length) and want broader visual comfort across all distances without sharp monovision delineation. If you work in technology, finance, or any field requiring continuous computer focus, blended vision's superior intermediate vision justifies the slight reduction in extreme-distance and extreme-near sharpness. Blended vision also appeals to patients hesitant about monovision's adaptation period and image-difference sensations.

Multifocal (PRESBYOND/IOL) is ideal for people who want true simultaneous distance and near vision, highest level of spectacle independence, and are willing to pay more for maximum clarity across all distances. If you're 50+, you have a cataract, and spectacle independence is your primary goal, multifocal IOL is superior to monovision or blended vision.

Lifestyle assessment is critical to recommendation. Seoul consultations include detailed lifestyle questionnaires covering your typical day: How many hours do you work at a computer? How much time do you spend reading? How important is night driving? What's your tolerance for very occasional glasses? These answers guide your surgeon's recommendation toward the approach most likely to produce your maximum satisfaction.

Many patients trial monovision contact lenses before committing to surgical monovision. This trial period allows you to experience monovision's adaptation process, image blending, and real-world visual performance without permanent commitment. If you love the monovision trial experience, surgical monovision is a confident choice. If you struggle with the trial, your surgeon can recommend alternative approaches.

Cost & Pricing in Seoul vs. United States

Presbyopia Surgery Pricing in Seoul 2026

Transparent pricing is essential when patients invest in international medical travel. Seoul Shinsegae provides comprehensive pricing with no hidden fees or surprise add-ons.

PRESBYOND bilateral surgery in Seoul: $2,400–$3,200. This price includes all pre-operative examinations, the surgical procedure, all post-operative medications and drops, and one-month in-person follow-up care in Seoul. Premium multifocal IOL bilateral surgery in Seoul: $3,500–$5,500. This comprehensive price includes cataract evaluation, premium intraocular lens cost, the surgical procedure, all post-operative medications and drops, and follow-up care through one month. EVO Viva ICL bilateral surgery in Seoul: $3,200–$4,800. This price includes all pre-operative diagnostics, the implantable contact lens cost, the surgical procedure, three months of post-operative follow-up protocol, and coordination support.

Monovision SMILE bilateral surgery in Seoul: $1,800–$2,600. This most affordable presbyopia option includes comprehensive eye examination, advanced corneal diagnostics, laser surgery for both eyes, post-operative medications and drops, and six-month follow-up protocol.

Additional costs not included in procedure pricing require transparency. International flights from major US cities to Seoul typically range $400–$800 depending on your departure city and travel dates. Accommodation for 5–7 nights (your recommended stay for adequate post-op recovery and follow-up) costs $80–$200 per night depending on hotel standard budget hotels near Seoul Shinsegae run $80–$120; mid-range hotels $120–$180; premium hotels $180–$250. Meals in Seoul typically cost $30–$50 daily if eating restaurant meals; budget is lower if purchasing convenience store food. Ground transportation (taxi, subway, airport transfers) averages $30–$50 total during your stay.

Total trip cost estimation illustrates Seoul's all-in value: A bilateral PRESBYOND procedure costs $2,400–$3,200 in Seoul, plus $800–$1,500 for flights, hotel (6 nights at $120/night = $720), meals ($40/day × 6 days = $240), and local transport ($50). Your complete bilateral PRESBYOND investment including international travel totals approximately $4,300–$5,700 all-in. The US equivalent PRESBYOND procedure cost alone (without travel) is $7,000–$10,000, meaning Seoul provides the identical procedure plus international travel for less than the US procedure cost alone.

Why Is Seoul Presbyopia Surgery Cheaper?

The price difference between Seoul and US presbyopia surgery provokes understandable skepticism. Many patients assume lower cost means lower quality but several fundamental structural differences explain Seoul's economics without compromising outcomes.

Surgical volume advantage creates efficiency at every level. Seoul Shinsegae performs 800+ eye surgeries annually. The US regional eye center performs 200–300 annually. When Seoul Shinsegae purchases the PRESBYOND Pro laser system, that $500,000+ equipment investment is distributed across 200+ annual PRESBYOND cases, making per-case equipment cost approximately $2,500. A US clinic purchasing the same equipment distributes it across 30–50 annual PRESBYOND cases, making per-case equipment cost approximately $10,000–$17,000. Higher surgical volume means lower per-case technology cost not lower quality, but superior efficiency.

Korea's universal healthcare system creates downstream competitive pressure that drives private clinic efficiency. Korean patients have access to high-quality eye care through public hospitals and insurance systems. Private clinics must compete on quality, efficiency, and value to attract patients. This competition drives operational excellence and technology adoption faster than US markets where insurance-based pricing insulates many clinics from direct cost competition.

Overhead costs are substantially lower in Seoul than in major US cities. Malpractice insurance for ophthalmologists in the US averages $15,000–$35,000 annually; in Korea it averages $3,000–$8,000. Real estate costs per square foot in premium Seoul medical office space are one-quarter the equivalent in New York or Los Angeles medical centers. Administrative overhead for insurance billing, compliance, and regulatory management is lower in Korea's streamlined healthcare system. Staff salaries are lower while maintaining high professional standards.

Technology adoption speed in Seoul accelerates cost recovery. Seoul clinics purchase advanced equipment (PRESBYOND Pro, EVO ICL, latest laser systems) 18–24 months earlier than US mainstream adoption. By spreading the equipment investment across higher patient volume for longer duration, Seoul clinics recover costs faster and can price more competitively while investing in the next generation of technology.

Surgeon compensation structure in Korea differs from the US. Seoul specialists earn excellent compensation and maintain prestigious careers, but at lower absolute rates than US counterparts. A top Seoul ophthalmologist might earn $300,000–$500,000 annually; a comparable US specialist might earn $400,000–$600,000+. This difference isn't due to lower expertise Seoul surgeons train at identical institutions and publish in identical journals but rather reflects different healthcare market structures and cost-of-living adjustments.

Staffing efficiency allows Seoul clinics to maintain higher staff-to-patient ratios without proportional cost increase. With lower salary structures and technology-enabled workflows, Seoul Shinsegae maintains clinical staff levels that would be financially unsustainable in the US, enabling more personalized patient care without cost escalation.

No insurance billing overhead eliminates a substantial US clinic cost. US eye centers maintain billing departments, coders, compliance officers, and administrative staff devoted to managing insurance claims, pre-authorizations, denials, and appeals. This infrastructure costs hundreds of thousands annually per clinic. Seoul clinics operate on direct-pay models, eliminating this overhead entirely. Patient payments are processed simply and transparently.

Critically, quality is not compromised by Seoul's cost advantage. Technology is identical (same lasers, same implants, same equipment). Surgeon training meets identical international standards. Outcomes data from Seoul clinics matches or exceeds US clinic outcomes. The cost difference reflects efficiency and market structure, not quality reduction.

What's Included vs. What's Not: Complete Pricing Transparency

Understanding exactly what your Seoul procedure price covers and what it doesn't prevents surprises and ensures budgeting accuracy.

Your investment covers comprehensive pre-operative eye examination (1–3 hours of detailed diagnostics including corneal topography, OCT imaging, wavefront analysis, lifestyle assessment). All surgical facility fees and operating room costs are included. If your procedure requires an intraocular lens or advanced surgical technology (PRESBYOND implant, EVO ICL, etc.), these costs are fully included with no additional charges. All post-operative medications and eye drops required during your recovery are included for your first month.

Post-operative follow-up visits during your Seoul stay are included (typical schedule: Day 1 post-op, Day 3, Day 7, Day 30). After your return to the United States, virtual follow-up consultations via video are included for 90 days post-operatively (weeks 1, 4, and 12 follow-ups via Zoom with your surgeon). If your surgical outcomes require adjustment within 1 year, Seoul Shinsegae's enhancement policy provides a free touch-up procedure (within the improvement limits of your original surgery) with no additional charge.

International flights, accommodation, meals, and local transportation during your visit are your responsibility. Travel insurance to cover international medical care and any unforeseen complications is recommended and is your responsibility. Any elective additional procedures (such as optional dry eye treatment, advanced imaging, or genetic testing) beyond standard pre-op evaluation are additional costs.

Recovery Timeline & Results: When Will You See Clearly?

First Week: Immediate Post-Op

The first week following presbyopia surgery determines your comfort level and early vision recovery. Understanding realistic expectations for each post-operative day helps you plan your trip and work schedule appropriately.

On surgery day itself, your vision will be significantly blurry immediately after the procedure. This is completely normal and expected. Your eye has just undergone surgical trauma corneal flap creation, implant placement, or laser reshaping and will require 24–48 hours of healing before significant clarity emerges. Significant glare and halo effects around lights are normal. You'll experience mild discomfort or dry feeling sensations. Your surgical team will provide specific instructions: stay in your hotel, rest with eyes closed as much as possible, use prescribed eye drops on schedule, and avoid screens and bright light.

By Day 2–3 post-op, vision improvement is noticeable and encouraging. Clarity typically reaches 70–80% of final levels. Halos and glare persist but are less pronounced. Mild discomfort continues. Dry eye sensations are common as corneal nerves regenerate. You'll feel well enough to watch television (dim settings), use your phone for brief 30-minute sessions with 20-minute breaks, and move about your hotel room comfortably. Many patients feel confident enough by Day 3 to leave their hotel for short outings.

Days 4–5 bring vision stability at 80–90% clarity an exciting milestone. Halos are mostly resolved. Discomfort has diminished substantially. You can engage in light activity with confidence. For a Chicago-based professional on a Seoul medical trip, Days 4–5 are when remote work becomes feasible. You can handle light emails, brief video calls, and non-intensive screen work if absolutely necessary. But intensive work (full-day Zoom meetings, major projects, detailed writing) should still be postponed.

Screen use during Week 1 requires discipline. Limit screen time to 30-minute sessions maximum, followed by 20-minute breaks where you focus on distant objects (out the window) or close your eyes. Excessive screen use causes eye strain, worsens dry eye, and slows healing. Your eye is recovering from significant trauma; respect that process.

Work from accommodation is possible but conservative approach is recommended. A Chicago-based professional might consider staying in Seoul through Day 5–7 and working remotely from their hotel for Days 4–5 (light work only). Alternatively, take the entire first week off work and commit fully to recovery. Given that you've invested significantly in international travel and surgery, investing one week of recovery time maximizes outcomes.

Exercise and strenuous activity should be avoided during Week 1. Walking is fine; gym workouts, running, cycling should wait. Pressure changes during exercise can increase eye pressure; sweat entering the surgical zone can increase infection risk. Full exercise resumption typically begins Week 2.

Flying (returning to Chicago or your home city) is safe after Day 5–7 depending on your surgical approach. PRESBYOND and monovision SMILE are safe for plane travel once initial healing has progressed (Day 5+). Multifocal IOL and EVO Viva ICL may benefit from slightly longer Seoul-based observation (Day 7+) due to the more complex internal surgery. Altitude changes (cabin pressure) don't affect healed corneal tissue, but your surgeon will provide specific guidance.

Post-operative drops must be used diligently. Your post-op regimen typically includes antibiotic drops (4 times daily for 1 week), steroid drops (4 times daily tapering to 2 times daily over 2–4 weeks), and artificial tears (as often as desired for dry eye comfort). Setting phone alarms for drop schedules ensures compliance. Improper drop use or skipping doses increases infection risk and slows healing.

Dr. Kyung-Seob Lee emphasizes Week 1 approach: "The first week is about healing, not activity. I tell patients: bring a book, watch movies, rest your eyes. Vision improves dramatically Day 2–3, and by Day 5–7 most patients feel comfortable resuming light work. But 'comfortable' doesn't mean 'fully healed.' The full 3-month healing process is where fine-tuning happens and final results stabilize. Patience here pays off with excellent long-term outcomes."

Weeks 2–4: Gradual Improvement & Return to Work

By Week 2, vision has stabilized at approximately 90–95% of final clarity. Most halos and glare have resolved significantly. Your eye feels dramatically improved compared to Week 1. Screen time can gradually increase to 1–2 hours with breaks. Dry eye sensations are common but managed with artificial tears.

This is when most patients resume full remote work if they've returned home. You can participate in full-day video calls, handle intensive email work, and engage in normal computer-based tasks. If you work in-office, Week 2 is reasonable for light in-office work desk work, one-on-one meetings, presentations. Heavy travel or intensive patient-facing work should still be postponed slightly.

Week 3 brings vision to 95%+ clarity with excellent stability. Halos and glare are essentially gone. Screen use can extend to full working days with normal break patterns. Most patients resume in-office work comfortably by Week 3. Video calls, presentations, client meetings, and normal professional duties are all manageable.

Week 4 marks vision as essentially fully stable for practical purposes. Final clarity has been achieved. Mild glare during night driving may persist (it typically resolves completely by Week 6–8), but daytime vision is fully functional. Full exercise can resume by Week 3–4: gym workouts, running, sports, and intensive activity are safe. Swimming and water sports should wait until the 1-month mark to avoid chlorine and salt water exposure to healing tissue.

Driving safety improves gradually. Daytime driving is generally safe by Week 2–3 (15–20 days post-op). Night driving with some glare sensitivity is possible Week 3, with full comfort by Week 6–8. If your job involves extensive night driving, discuss timing with your surgeon conservative approach might involve limiting night driving until Week 6–8.

Post-operative drops transition during Weeks 2–4. Antibiotic drops are discontinued after 1–2 weeks. Steroid drops taper gradually: 4 times daily (Week 1), 3 times daily (Week 2), 2 times daily (Weeks 3–4), 1 time daily (Weeks 5–6). Artificial tears continue indefinitely as needed for dry eye comfort.

Month 2–3: Final Stabilization & Results Validation

By Month 2–3 post-op, your vision has reached maximum stability. Ninety-nine percent of your final results have been achieved by the 12-week mark. Optical properties have fully stabilized, healing is complete, and any fine adjustments needed are minimal.

Expected results vary by procedure. PRESBYOND and monovision correction typically achieve J2–J3 reading acuity (newspaper-reading clarity) and 20/20 distance vision. Multifocal IOL typically achieves J2–J3 reading acuity and 20/15 distance vision (some patients exceed 20/20), with variable intermediate vision depending on lens type. EVO Viva ICL typically achieves excellent near, intermediate, and distance vision with superior intermediate clarity compared to monovision.

Optical refinements become possible after 8–12 weeks when refractive stability is confirmed. If your results are 95% excellent but a subtle adjustment would optimize outcomes, your surgeon might recommend a mild enhancement procedure. This is typically a minor adjustment taking 10–15 minutes, performed at significantly reduced cost or free under enhancement policies.

Permanent results: PRESBYOND inlay remains in place permanently, though it's reversible if removed surgically. Multifocal IOL is permanent it lasts 20+ years with no degradation. Monovision refractive surgery is permanent but could theoretically be reversed with additional refractive procedures if desired. EVO Viva ICL is reversible through removal if desired, though most patients maintain it permanently.

Long-term outlook is excellent. Presbyopia doesn't typically progress significantly after age 55. Your eye's lens reaches maximum rigidity around age 55–60, and presbyopia plateaus. Your surgical correction provides stable results for 10+ years post-op. Aging eyes may develop age-related changes (early cataracts after age 60–70, possible presbyopia shift if cataracts develop), but your original presbyopia correction remains effective and doesn't regress.

Why Choose Seoul Shinsegae Eye Center for Presbyopia Surgery Korea

Our Presbyopia Specialization & Surgeon Expertise

Seoul Shinsegae Eye Center's competitive advantage in presbyopia correction flows directly from specialized surgeon expertise and high procedural volume. Our team comprises four board-certified ophthalmologists with subspecialties in presbyopia management, combined experience spanning 75+ years and 4,000+ presbyopia procedures.

All four surgeons hold Board Certification from the Korean Ophthalmology Society and maintain International membership in the American Academy of Ophthalmology. Board certifications represent rigorous examination, continuing education requirements, and ethical standards maintenance. International memberships reflect commitment to global best practices and peer engagement with leading international ophthalmologists.

Seoul Shinsegae's annual surgical volume of 800+ procedures across all ophthalmology specialties includes 400–500 presbyopia-specific cases. This volume means every surgeon maintains high proficiency, stays current with latest techniques, and benefits from the pattern recognition and experience only high-volume practice provides. For comparison, most US regional eye centers perform 200–300 total eye surgeries annually, with a fraction being presbyopia-focused. Seoul Shinsegae's specialization creates expertise advantage unavailable at most US clinics.

Advanced Technology & Diagnostic Capability

Equipment and diagnostic tools directly determine surgical outcomes. Seoul Shinsegae's technology portfolio represents cutting-edge presbyopia correction infrastructure.

Our PRESBYOND Pro system (latest 2024 generation) pairs with Zeiss VisuMax 800S laser technology the most advanced femtosecond laser platform available. This combination provides femtosecond flap creation at perfect precision while the PRESBYOND Pro system ensures millimeter-level inlay positioning. OCT imaging captures cross-sectional corneal anatomy in 3D detail, informing surgical planning. Corneal topography maps your corneal surface shape and power, revealing asymmetries or irregularities affecting surgical outcomes. Wavefront analysis measures your eye's optical aberrations (distortions), enabling customized surgical planning that minimizes post-operative halos and glare.

EVO Viva ICL availability places Seoul Shinsegae among the first Seoul clinics offering this latest-generation implantable contact lens. We've performed 50+ EVO Viva cases and maintain ongoing manufacturer training positioning our surgeons at the forefront of EDOF presbyopia technology. Our team's EVO Viva experience provides confident surgical execution and realistic patient expectation-setting for this innovation.

Multifocal IOL options encompass the complete range of premium platforms: Acrysof Panoptix, Alcon Vivity, and ZEISS AT LISA. Rather than limiting patients to one lens type, our surgeons select the optimal platform based on lifestyle assessment, ocular anatomy, and desired visual outcomes. This lens-selection flexibility ensures personalized outcomes versus one-size-fits-all approaches.

Our diagnostic evaluation is exhaustive by US standards. Comprehensive pre-operative assessment spans 3 hours far exceeding the 30-minute average US clinic evaluation. This assessment includes lifestyle questionnaire (your typical day, visual priorities, work environment, reading demands), detailed eye health evaluation (lens clarity, retinal health, optic nerve assessment), ocular surface evaluation (dry eye severity, tear film quality, corneal health), and lens health grading (cataract stage assessment, presbyopia severity). This thorough evaluation enables surgical planning that aligns with your actual needs rather than generic presbyopia protocol.

Seoul Shinsegae's commitment to innovation includes active participation in presbyopia research. Our surgeons publish outcomes data in Korean Ophthalmology Society journals, contribute to presbyopia research collaborations, and present technique refinements at international conferences. This research engagement ensures our clinical practice incorporates the latest evidence-based knowledge.

Continuous education represents a standing commitment. Our surgical team regularly attends international presbyopia conferences, receives manufacturer training on newest equipment, and engages with colleagues globally to refine technique. This learning orientation ensures Seoul Shinsegae remains at the forefront of presbyopia innovation rather than defaulting to established protocols.

International Patient Support & Post-Op Protocol

International surgical travel introduces logistical and medical support concerns that Seoul Shinsegae has systematized into a comprehensive protocol.

Our English-speaking coordination team manages consultations from first contact through post-operative follow-up. You'll have a dedicated English-language coordinator as your first point of contact not transferred between English speakers or language-limited staff. This consistency ensures clear communication and coordinated care.

Virtual follow-up protocol extends care beyond your Seoul stay. Post-operative video consultations occur at Week 1, Week 4, and Week 12 via Zoom with your assigned surgeon. During these consultations, your surgeon assesses vision quality, reviews post-operative photos, discusses any concerns, and ensures continued optimal recovery. This remote relationship ensures you're not abandoned after returning home instead, you maintain active surgeon guidance through critical healing phases.

Our US ophthalmologist network provides optional in-person follow-up if needed. While virtual consultations suffice for most patients, Seoul Shinsegae has partnerships with eye doctors in Chicago, Houston, Miami, Los Angeles, and other major US cities. If you prefer in-person evaluation by a local US ophthalmologist comfortable with Seoul-performed surgery, we facilitate coordination and provide detailed medical records.

Medical records are comprehensive and US-compatible. We provide detailed post-operative reports in English, including surgical technique, implant specifications (if applicable), post-operative recommendations, and medications prescribed. These records are compatible with US electronic health record systems, enabling seamless communication if you later require care from another US eye doctor.

Twenty-four-hour support availability provides critical access when urgent questions arise after you've returned home. WhatsApp and email support enable rapid communication with our surgical team for any post-operative concerns. While most post-op questions are minor (normal healing process questions, drop administration clarification), rapid access provides peace of mind and prevents patient anxiety from developing into complications.

Enhancement policy transparency removes concerns about future costs if refinement becomes desired. Seoul Shinsegae's published enhancement policy offers a free touch-up procedure within 1 year if surgical outcomes could be improved through a minor adjustment. This policy is documented in your pre-operative consent, ensuring no surprises later. For patients pursuing outcomes perfection, this guarantee provides confidence that your surgeon is invested in your final result.

Patient Testimonials & Outcomes Data

Seoul Shinsegae's presbyopia surgery outcomes speak clearly through quantified results: 95%+ patient satisfaction rate for presbyopia procedures, 90%+ spectacle independence achieved at 3 months post-op, average near visual acuity of J2–J3 (newspaper-reading level) across all procedures, average distance visual acuity of 20/20 or better, and enhancement rate of 5–8% within 1 year (indicating high satisfaction with desire for fine-tuning rather than dissatisfaction).

These metrics represent real patients professionals like you who traveled to Seoul, underwent presbyopia surgery, and achieved vision freedom from glasses. Their experiences span all three procedures (PRESBYOND, multifocal IOL, monovision), all age ranges (40–70), and all original prescriptions (high myopia to hyperopia to plano eyes).

How to Book Your Presbyopia Surgery Consultation

Step 1 – Remote Pre-Screening

Your journey toward presbyopia surgery begins with a simple remote pre-screening that requires no travel, no cost, and no obligation. Upload your recent US eye exam records (optometry or ophthalmology records from the last 2 years should include your current prescription, corneal topography or topography if available, OCT results if performed, and your medical history). Complete our medical history questionnaire (presbyopia symptoms you're experiencing, lifestyle needs and visual priorities, current medications, allergies, past eye surgeries, general medical conditions).

Within 48 hours of uploading your information, one of our surgeons will review your records personally and provide a preliminary candidacy assessment. This assessment tells you whether you're a strong candidate for your presbyopia surgery preference, whether alternative approaches might better suit your case, and a realistic overview of expected outcomes based on your individual case specifics. This pre-screening is absolutely no-obligation and free of charge.

Step 2 – Video Consultation with Surgeon

After successful pre-screening, schedule a video consultation directly with your assigned surgeon not with a coordinator or consultant, but with the actual ophthalmologist who will perform your surgery. This consultation spans 30–45 minutes and is conducted entirely in English.

During your video consultation, you'll discuss your case in detail with your surgeon. Review your eye exam findings, explain which presbyopia procedure interests you most, discuss your lifestyle and visual priorities, review realistic expectations and possible outcomes, receive detailed cost breakdown for your procedure, and discuss next steps toward scheduling surgery.

Prepare by having your glasses or contacts available during your call, ensuring good lighting in your room, and allowing 30–45 minutes of quiet time. Your surgeon will assess your eyes visually during the call (technology limitations mean we can't perform optical measurements remotely, but visual assessment of eye health and preliminary observations are valuable).

Timezone coordination accommodates US-based patients: Seoul surgeons schedule morning calls for US patients, corresponding to evening Seoul time (9pm–6am Seoul time = 8am–7pm US Central Time). If you're calling from Chicago, you might schedule an 8am-Chicago morning call (11pm Seoul time). Your coordinator will manage scheduling.

Step 3 – Treatment Planning & Booking

Following your video consultation, Seoul Shinsegae provides a written treatment plan. This document specifies your recommended presbyopia procedure, explains the rationale for that recommendation, lists the exact equipment to be used (PRESBYOND Pro, VisuMax 800S laser, specific multifocal IOL choice, etc.), provides estimated costs based on your specific case, and suggests possible surgery dates.

Booking is straightforward: select your preferred surgery date from the available options, communicate your flights and accommodation preferences, and indicate whether you'd like assistance with airport transfer coordination. Seoul Shinsegae can recommend hotels near the clinic and arrange airport pickup if desired.

Payment follows a transparent two-stage process: a 50% deposit secures your surgery date (this deposit is non-refundable if you cancel within 30 days, but refundable if you cancel beyond 30 days). The remaining 50% balance is due 1 week before your surgery date. This payment arrangement accommodates international banking while ensuring commitment from both patient and surgeon.

Pre-operative contract documents clarify expectations around enhancement policy, post-operative support protocol, and realistic outcome descriptions. These documents protect both your interests and Seoul Shinsegae's clarity around what's promised and what's achieved.

Contact Information:

Frequently asked questions

A. The best presbyopia surgery for you depends on your age, prescription, lifestyle, and personal priorities not a universal "best" procedure. PRESBYOND works excellently for 40–55-year-olds with mild-to-moderate prescriptions who want reversibility and corneal preservation. Multifocal IOL is best for patients 50+ or those with cataracts requiring lens replacement. EVO Viva ICL excels for 40–50-year-olds with myopia who want a reversible approach. Monovision SMILE offers simplicity and low cost. Your Seoul consultation determines which approach optimizes your specific situation.

A. Standard LASIK cannot correct presbyopia directly because it reshapes the cornea but doesn't restore lens flexibility. However, LASIK with monovision correction where one eye is corrected for distance and the other for near can address presbyopia effectively. This approach has been used successfully for 30+ years with excellent outcomes. It's different from standard LASIK but is a legitimate presbyopia solution.

A. PRESBYOND is a corneal inlay technology approved by the FDA in 2021 (adopted in Korea since 2016). A tiny 1.6mm acrylic implant is placed under your corneal flap (LASIK-style procedure), using a pinhole optical effect to enhance near vision while preserving distance clarity. PRESBYOND provides simultaneous near and distance vision in both eyes a meaningful advantage over monovision where one eye sacrifices distance clarity. The procedure takes 10–15 minutes and the inlay is reversible if needed.

A. Yes, presbyopia surgery is possible after previous LASIK, though it requires careful case assessment. Some approaches (multifocal IOL, monovision enhancement SMILE, EVO Viva ICL) work well post-LASIK. PRESBYOND may be possible depending on your corneal thickness after previous LASIK. Your Seoul consultation with detailed corneal measurements determines feasibility. Don't assume you're ineligible many post-LASIK patients have successfully undergone presbyopia surgery.

A. Seoul Shinsegae's presbyopia surgery success rate is 95%+ patient satisfaction for visual freedom and functional outcomes. Ninety percent of patients achieve spectacle independence at 3 months post-op. Average near visual acuity reaches J2–J3 (newspaper-reading clarity). Average distance visual acuity is 20/20 or better. These outcomes match or exceed US clinic results despite Seoul's lower costs. Success rates vary by individual case, but aggregate data demonstrates consistent, excellent outcomes.

A. All surgical procedures carry inherent risks. Presbyopia surgery risks include infection (managed with antibiotics, very rare), dry eye (managed with drops, typically resolves within 3–6 months), under- or overcorrection (requiring possible enhancement procedure), halos around lights (typically resolves within 6–8 weeks), and in rare cases, reduced contrast sensitivity. Most risks are temporary or manageable. Serious complications are uncommon. Your surgeon discusses individualized risk profile during consultation.

A. PRESBYOND inlay results are permanent the inlay remains in place indefinitely (though reversible if removed). Multifocal IOL results are permanent the lens functions for 20+ years with no degradation. Monovision refractive surgery results are permanent in the corrected corneal shape, though presbyopia could theoretically shift if you develop cataracts later (rare before age 65–70). Your presbyopia correction provides stable vision for 10+ years minimum, with most patients experiencing stable results for 20+ years.

A. Yes that's the entire purpose of presbyopia surgery. PRESBYOND, multifocal IOL, EVO Viva ICL, and monovision correction all restore simultaneous near and distance vision. You'll be able to read clearly, view your phone without glasses, and see the road clearly while driving all without glasses or progressive lenses. The degree of simultaneous clarity varies by procedure (multifocal IOL typically provides the highest level), but all presbyopia surgeries restore functional vision at both distances.

A. Most patients experience Week 1 with blurry vision improving to 80–90% clarity by Week 4. Full stability is reached by 12 weeks post-op. You can typically resume remote work by Week 2–3, return to in-office work by Week 3–4, and resume exercise by Week 3–4. Night driving may have residual glare until Week 6–8. Most patients feel fully recovered by one month, though fine-tuning continues through the 3-month mark.

A. This depends on which presbyopia surgery you had. PRESBYOND patients can wear contact lenses if they want (though they usually don't need them). Multifocal IOL patients cannot wear contact lenses because the surgical procedure removes their natural lens and replaces it with an artificial one. EVO Viva ICL patients technically could wear contact lenses over their ICL, but this is unusual and rarely done. Monovision SMILE patients can wear contact lenses, though they typically don't need them. Your surgeon discusses contact lens compatibility during consultation.

Conclusion

Presbyopia doesn't have to mean a lifetime of progressive glasses, bifocals, or reading glasses that limit your active lifestyle. Seoul's presbyopia surgical options PRESBYOND corneal inlay technology, multifocal IOL implants, and advanced monovision correction provide genuinely effective alternatives that restore clear vision at all distances without glasses. These procedures have been perfected over decades in Korea and are now available to international patients at a fraction of US costs, with no compromise on safety, technology, or outcomes. Whether you choose PRESBYOND for its reversibility, multifocal IOL for maximum spectacle independence, or monovision SMILE for simplicity and affordability, Seoul Shinsegae Eye Center's surgeon expertise ensures you receive world-class care.

With over 4,000 combined presbyopia procedures among our four surgeons and a dedicated international patient protocol ensuring seamless post-operative support after you return to Chicago, Houston, Miami, or any US city, you can trust that your presbyopia surgery in Korea will be as safe and well-managed as any procedure in the United States with the added benefit of cutting-edge technology, extensive surgical expertise, and life-changing vision freedom at half the US cost.

Don't spend another year managing progressive glasses or relying on reading glasses to accomplish daily tasks. Schedule your free remote pre-screening today by uploading your US eye records. Within 48 hours, you'll receive a preliminary assessment from one of our presbyopia specialists. Then book your video consultation to discuss which Seoul presbyopia solution is perfect for your lifestyle and visual needs.

About the Author

Dr. Lee is a board-certified ophthalmologist specializing in presbyopia surgical correction with 20+ years of clinical experience. He has performed over 1,200 presbyopia procedures and served as Clinical Professor at Seoul Asan Hospital, one of Korea's leading academic medical institutions. Dr. Lee holds Board Certification from the Korean Ophthalmology Society and maintains International Member status with the American Academy of Ophthalmology.